Stereotaxical infusion of rotenone: a reliable rodent model for Parkinson's disease.

PloS One
N XiongT Wang

Abstract

A clinically-related animal model of Parkinson's disease (PD) may enable the elucidation of the etiology of the disease and assist the development of medications. However, none of the current neurotoxin-based models recapitulates the main clinical features of the disease or the pathological hallmarks, such as dopamine (DA) neuron specificity of degeneration and Lewy body formation, which limits the use of these models in PD research. To overcome these limitations, we developed a rat model by stereotaxically (ST) infusing small doses of the mitochondrial complex-I inhibitor, rotenone, into two brain sites: the right ventral tegmental area and the substantia nigra. Four weeks after ST rotenone administration, tyrosine hydroxylase (TH) immunoreactivity in the infusion side decreased by 43.7%, in contrast to a 75.8% decrease observed in rats treated systemically with rotenone (SYS). The rotenone infusion also reduced the DA content, the glutathione and superoxide dismutase activities, and induced alpha-synuclein expression, when compared to the contralateral side. This ST model displays neither peripheral toxicity or mortality and has a high success rate. This rotenone-based ST model thus recapitulates the slow and specific loss of...Continue Reading

References

Jan 1, 1975·Biochemical Pharmacology·C Sachs, G Jonsson
Feb 1, 1989·Journal of Neurochemistry·P RiedererM B Youdim
Nov 17, 1994·Annals of the New York Academy of Sciences·K P MohanakumarC C Chiueh
Dec 2, 2000·Nature Neuroscience·R BetarbetJ T Greenamyre
Jul 5, 2001·Environmental Research·A PriyadarshiS S Priyadarshi
Apr 12, 2002·BioEssays : News and Reviews in Molecular, Cellular and Developmental Biology·Ranjita BetarbetJ Timothy Greenamyre
May 2, 2002·The Journal of Neuropsychiatry and Clinical Neurosciences·James Parkinson
Oct 12, 2002·Proceedings of the National Academy of Sciences of the United States of America·William DauerRene Hen
Dec 25, 2002·Neurobiology of Aging·Heiko BraakEva Braak
Feb 10, 2004·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Nicolas LapointeFrancesca Cicchetti
Oct 27, 2004·Cell and Tissue Research·Andreas Schober
Feb 18, 2005·Proceedings of the National Academy of Sciences of the United States of America·Francesco FornaiThomas C Südhof
Sep 6, 2005·Environmental Health Perspectives·Philip J LandriganDaniel Droller
Dec 16, 2005·Proceedings of the National Academy of Sciences of the United States of America·Benoît ZuberJacques Dubochet
Jul 11, 2006·The Journal of Clinical Investigation·Joseph M SavittTed M Dawson
Mar 17, 2007·Lancet Neurology·Marta Martinez-Vicente, Ana Maria Cuervo
Dec 20, 2007·Nuclear Medicine Communications·Wei CaoYongxue Zhang
Dec 25, 2007·Journal of Pharmacological and Toxicological Methods·Paulien G M RavenstijnElizabeth C M de Lange
Jan 4, 2008·The Journal of Clinical Investigation·Marta Martinez-VicenteAna Maria Cuervo
Jan 10, 2008·Journal of Neurochemistry·Edward D PloweyCharleen T Chu
Mar 14, 2009·Parkinsonism & Related Disorders·Masayuki Yokochi
Feb 19, 2009·Journal of Huazhong University of Science and Technology. Medical Sciences = Hua Zhong Ke Ji Da Xue Xue Bao. Yi Xue Ying De Wen Ban = Huazhong Keji Daxue Xuebao. Yixue Yingdewen Ban·Zhentao ZhangLan Wang
Apr 21, 2009·Lancet Neurology·K Ray Chaudhuri, Anthony H V Schapira

❮ Previous
Next ❯

Citations

Jun 7, 2013·Journal of Molecular Evolution·Matheus de Souza GomesCharles Spillane
Jul 15, 2011·Journal of Inherited Metabolic Disease·Megan E BreuerJan A M Smeitink
Feb 1, 2012·Apoptosis : an International Journal on Programmed Cell Death·Heewon KangYoung J Oh
Jan 31, 2013·Molecular Neurobiology·Stephen Mullin, Anthony Schapira
Jan 13, 2015·Molecular Neurobiology·Jing XiongTao Wang
Feb 3, 2016·Frontiers in Neuroscience·Shail A JagmagSukant Khurana
Mar 20, 2012·Neurobiology of Disease·M E BreuerJ A M Smeitink
Nov 19, 2011·Free Radical Biology & Medicine·Hui ZhouHui-Ming Gao
Sep 20, 2011·Journal of Biotechnology·Tiziana Alberio, Mauro Fasano
Mar 19, 2013·Behavioral and Brain Functions : BBF·Nian XiongTao Wang
Mar 20, 2015·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·Tan WangBeisha Tang
Sep 28, 2013·Neuroscience·M Sonia AngelineP Kumar
Jan 8, 2015·Frontiers in Neuroanatomy·Javier Blesa, Serge Przedborski
Nov 25, 2016·Redox Report : Communications in Free Radical Research·S Narasimhan Kishore KumarPeriandavan Kalaiselvi
Nov 24, 2016·Brain Research·Zhen-Nian ZhangDing-Fang Cai

❮ Previous
Next ❯

Methods Mentioned

BETA
MDA

Software Mentioned

SPSS
Pro plus
Image

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Antiparasitics

Antiparasitics are medications which are indicated for the treatment of parasitic diseases. Discover the latest research on antiparasitics here.

Alpha-Synuclein Aggregation (MDS)

Alpha-synucleins are small proteins that are believed to restrict the mobility of synpatic vesicles and inhibit neurotransmitter release. Aggregation of these proteins have been linked to several types of neurodegenerative diseases including dementia with Lewy bodies and Parkinson's disease. Here is the latest research on α-synuclein aggregation.

Amygdala and Midbrain Dopamine

The midbrain dopamine system is widely studied for its involvement in emotional and motivational behavior. Some of these neurons receive information from the amygdala and project throughout the cortex. When the circuit and transmission of dopamine is disrupted symptoms may present. Here is the latest research on the amygdala and midbrain dopamine.